Clinical trials: TCC
Vascular Access for Hemodialysis and Inflammation
Vascular Access for Hemodialysis and Inflammation
The aim of the present study was to investigate patients free of active infection and/or thrombosis to assess if the type of vascular access (AVF, AVG, TCC), could influence: 1.
- Trial name
- NCT00850707
- Where
- Italy
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bladder Cancer
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
The goal of this clinical research study is to learn if whole brain radiation can lower the chances of developing brain tumors in patients with small cell carcinoma of the urinary tract, including the bladder.
- Trial name
- NCT00756639
- Testing
- Prophylactic Cranial Irradiation (PCI), Brain X-ray
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Transitional Cell Carcinoma, Bladder Cancer
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
In this research study the investigators are looking to see if the combination of docetaxel plus Vandetanib is effective in the treatment of metastatic transitional cell carcinoma (TCC).
- Trial name
- NCT00880334
- Testing
- Docetaxel, vandetanib
- Where
- 3 sites in United States
- Volunteers
- 149 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
The study is investigating the ability of UroGen's UGN-101 to treat urothelial carcinoma tumors from the upper urinary tract.
- Trial name
- Olympus (NCT02793128)
- Testing
- UGN-101 instillations
- Where
- 24 sites in United States, Israel
- Volunteers
- 71 people
- Sponsor
- UroGen Pharma Ltd.
Urothelial Cancer
The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy
- Trial name
- AFINIVEST (NCT01801137)
- Testing
- Everolimus (Afinitor®)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hopital Foch
Metastatic Transitional Cell Cancer of the Urothelial Tract
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract.
- Trial name
- NCT03159143
- Testing
- Docetaxel, Oxaliplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Leonard Appleman
Paroxysmal Nocturnal Hemoglobinuria
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)
A safety and immunogenicity study in long-term treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in patients with paroxysmal nocturnal hemoglobinuria, who have been involved earlier in the clinical trials of Eculizumab…
- Trial name
- NAP (NCT04679103)
- Testing
- Eculizumab (JSC GENERIUM, Russia)
- Where
- 9 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AO GENERIUM
Bladder Cancer
Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients
In many of urothelial carcinoma patients, one does not find common risk factors such as smoking. The medical center is located in an industrial city with known air and water pollution.
- Trial name
- NCT02811952
- Testing
- without intervention
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Carmel Medical Center
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03935347
- Testing
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268450
- Testing
- bevacizumab, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Urologic Neoplasms
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell…
- Trial name
- NCT00034177
- Testing
- S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel
- Volunteers
- 27 people
- Sponsor
- Achieve Life Sciences
Transitional Cell Carcinoma of the Bladder
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
- Trial name
- NCT00859339
- Testing
- Gemcitabine, Cisplatin, Sunitinib Malate
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Noah Hahn, M.D.
Bladder Cancer, Bladder Carcinoma
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
Bladder preservation in patients with complete response after neoadjuvant chemotherapy will lead to equivalent or superior relapse free rates compared to cystectomy rates from historical controls.
- Conditions
- Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, Muscle Invasive Bladder Carcinoma
- Trial name
- NCT02145390
- Testing
- Transurethral Resection of the Bladder Tumor & Cystoscopy, Intensity Modulated Radiation Therapy, Expanded Prostate Cancer Index Composite Short Form 12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Bipolar Disorder, Anxious Disorder
Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response
The purpose of this study is to determine whether a Cognitive and Behavioral group Therapy (CBT) + Mindfulness Based Cognitive Therapy (MBCT) decreased relapses and hospitalizations and improved outcomes (depressive and manic…
- Conditions
- Bipolar Disorder, Anxious Disorder, Alcohol Dependence
- Trial name
- TCC-MBCT (NCT02472483)
- Testing
- Cognitive and Behavior Therapy (CBT), Mindfulness Based Cognitive Therapy (MBCT)
- Where
- France
- Volunteers
- 158 people
- Sponsor
- Centre Hospitalier St Anne
Transitional Cell Carcinoma, Bladder Neoplasms
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium.
- Conditions
- Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms, Ureter Neoplasms
- Trial name
- NCT00101608
- Testing
- vinflunine
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Transitional Cell Carcinoma
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
This study is designed to evaluate response and survival of treatment with the combination of pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune checkpoint inhibitor treatment.
- Trial name
- NCT04179110
- Testing
- Pembrolizumab and Ramucirumab
- Where
- United States
- Sponsor
- Yale University
Hepatocellular Cancer (HCC)
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with…
- Trial name
- NCT07321613
- Testing
- Thalidomide (50mg), carmofur, compound mylabris capsule
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Shanghai Zhongshan Hospital
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline
Bladder Cancer
Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors
The goal of this clinical research study is to use computed tomography urography (CTU) scans and intravenous urography (IVU) scans to check the status of urothelial cancer, in order to try to learn the level of effectiveness of…
- Trial name
- NCT00567684
- Testing
- Computed Tomography Urography (CTU), Intravenous Urography (IVU)
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- M.D. Anderson Cancer Center
Transitional Cell Carcinoma
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
The purpose of this study is to evaluate the efficacy of Gemcitabine plus Ifosfamind as second line chemotherapy in advanced transitional cell carcinoma in terms of response rate and overall survival .
- Trial name
- NCT00173862
- Testing
- Gemcitabine, Ifosfamide
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital